<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01978782</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF12.04</org_study_id>
    <secondary_id>2012-005148-50</secondary_id>
    <nct_id>NCT01978782</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).</brief_title>
  <acronym>RECITAL</acronym>
  <official_title>Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression is the most common mental health disorder among HIV-patients. Recognizing and&#xD;
      treating depression is important in order to improve quality of life and health outcomes in&#xD;
      those living with HIV. In clinical practice selective serotonin reuptake inhibitors (SSRIs)&#xD;
      are used most frequently in HIV patients with depressive symptoms. A complicating factor in&#xD;
      the concomitant use of antiretroviral agents and antidepressant therapy is the occurrence of&#xD;
      drug-drug interactions. Citalopram can be seen as one of the preferred SSRIs in HIV-infected&#xD;
      patients because citalopram has a relatively favourable drug interaction profile compared to&#xD;
      other SSRIs. Raltegravir is an HIV-1 integrase inhibitor and is frequently being used as&#xD;
      antiretroviral agent in combination with tenofovir/emtricitabine in HIV-patients. Raltegravir&#xD;
      has shown sustained antiretroviral activity, is generally well tolerated and has little&#xD;
      propensity to interact with other drugs because it does not inhibit or induce CYP450 enzymes.&#xD;
      Theoretically, no clinically relevant drug interaction is expected between raltegravir and&#xD;
      citalopram as raltegravir is not a CYP2D6 substrate and thus will not be affected by the&#xD;
      possible inhibition of CYP2D6 by citalopram. Raltegravir is metabolized by UGT but citalopram&#xD;
      is not known to influence UGT. A possible interaction may occur through inhibition of P-gp&#xD;
      mediated transport of raltegravir by citalopram. However, even when no drug interaction is&#xD;
      expected theoretically, it may be recommended to collect sufficient clinical evidence to&#xD;
      support this hypothesis because unexpected interactions with raltegravir have been observed&#xD;
      in the past. In order to be able to recommend raltegravir and citalopram concomitant use, a&#xD;
      pharmacokinetic study in healthy volunteers is proposed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>raltegravir AUC and citalopram AUC</measure>
    <time_frame>at steady state: day 5 of raltegravir treatment and day 16 or later for citalopram</time_frame>
    <description>To assess the effect of multiple dose citalopram on the steady state pharmacokinetics of raltegravir and vice versa by intrasubject comparison in healthy subjects.&#xD;
The comparison of steady state raltegravir (400 mg BID for 5 days) pharmacokinetics (AUC0-12h, Cmax, C12h) with steady state citalopram (20 mg QD) vs. raltegravir alone by intrasubject comparison.&#xD;
The comparison of steady state citalopram (20 mg QD) pharmacokinetics (AUC0-24h, Cmax, C24h) with steady state raltegravir (400 mg BID) vs. citalopram alone by intrasubject comparison.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to approximately 13 weeks (from screening until the last study visit)</time_frame>
    <description>Adverse events will be scored and laboratory measurements for safety will be collected frequently from screening onwards (maximum 4 weeks before the start of the study) until the last study visit (Day 60) or longer if applicable.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>raltegravir alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>raltegravir 400 mg BID for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>citalopram alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>citalopram 10 mg QD for 3 days, followed by citalopram 20 mg QD for 13-14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>raltegravir + citalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>raltegravir 500 mg BID and citalopram 20 mg QD for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <arm_group_label>raltegravir + citalopram</arm_group_label>
    <arm_group_label>raltegravir alone</arm_group_label>
    <other_name>isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citalopram</intervention_name>
    <arm_group_label>citalopram alone</arm_group_label>
    <arm_group_label>raltegravir + citalopram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is at least 18 and not older than 55 years at screening.&#xD;
&#xD;
          2. Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at&#xD;
             least 3 months prior to Day 1.&#xD;
&#xD;
          3. Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included.&#xD;
&#xD;
          4. Subject is able and willing to sign the Informed Consent Form prior to screening&#xD;
             evaluations.&#xD;
&#xD;
          5. Subject is in good age-appropriate health condition as established by medical history,&#xD;
             physical examination, electrocardiography, results of biochemistry, haematology and&#xD;
             urinalysis testing within 4 weeks prior to Day 1. Results of biochemistry, haematology&#xD;
             and urinalysis testing should be within the laboratory's reference ranges. If&#xD;
             laboratory results are not within the reference ranges, the subject is included on&#xD;
             condition that the Investigator judges that the deviations are not clinically&#xD;
             relevant. This should be clearly recorded.&#xD;
&#xD;
          6. Subject has a normal blood pressure and pulse rate, according to the Investigator's&#xD;
             judgement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.&#xD;
&#xD;
          2. Positive HIV test.&#xD;
&#xD;
          3. Positive hepatitis B or C test.&#xD;
&#xD;
          4. Pregnant female (as confirmed by an hCG test performed less than 4 weeks before day 1)&#xD;
             or breast-feeding female. Female subjects of childbearing potential without adequate&#xD;
             contraception, e.g. hysterectomy, bilateral tubal ligation, (non-hormonal)&#xD;
             intrauterine device, total abstinence, double barrier methods, or two years&#xD;
             post-menopausal. They must agree to take precautions in order to prevent a pregnancy&#xD;
             throughout the entire conduct of the study.&#xD;
&#xD;
          5. Therapy with any drug (for two weeks preceding Day 1), except for acetaminophen.&#xD;
&#xD;
          6. Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular&#xD;
             disorders, neurological disorders (especially seizures and migraine), psychiatric&#xD;
             disorders, gastro-intestinal disorders, renal and hepatic disorders, hormonal&#xD;
             disorders (especially diabetes mellitus), coagulation disorders.&#xD;
&#xD;
          7. Relevant history or presence of QT syndrome, prolonged QTc time, bradycardia,&#xD;
             hypokalaemia or hypomagnesaemia, recent acute myocardial infarction, or uncompensated&#xD;
             heart failure.&#xD;
&#xD;
          8. Relevant history or current condition that might interfere with drug ab-sorption,&#xD;
             distribution, metabolism or excretion.&#xD;
&#xD;
          9. History of or current abuse of drugs, alcohol or solvents.&#xD;
&#xD;
         10. Inability to understand the nature and extent of the study and the pro-cedures&#xD;
             required.&#xD;
&#xD;
         11. Participation in a drug study within 60 days prior to Day 1.&#xD;
&#xD;
         12. Donation of blood within 60 days prior to Day 1.&#xD;
&#xD;
         13. Febrile illness within 3 days before Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRCN Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://regist2.virology-education.com/abstractbook/2015_4.pdf</url>
    <description>Abstract 53: Pharmacokinetic drug-drug interaction study between raltegravir and citalopram in healthy volunteers.</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/26375942/</url>
    <description>paper</description>
  </link>
  <results_reference>
    <citation>Blonk MI, Langemeijer CC, Colbers AP, Hoogtanders KE, van Schaik RH, Schouwenberg BJ, Burger DM. Pharmacokinetic drug-drug interaction study between raltegravir and citalopram. Antivir Ther. 2016;21(2):143-52. doi: 10.3851/IMP2993. Epub 2015 Sep 16.</citation>
    <PMID>26375942</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2013</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>raltegravir</keyword>
  <keyword>citalopram</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>drug-drug interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

